Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
52 studies found for:    "Raynaud Disease"
Show Display Options
Rank Status Study
21 Completed Lab Study of MQX-503 in Treatment of Raynaud's
Conditions: Raynaud Disease;   Raynaud Disease Secondary to Scleroderma;   Raynaud Secondary to Other Autoimmune Disease
Intervention: Drug: topical organogel with nitroglycerin
22 Unknown  Prognostic Influence of Light Rheography Measurement of Patients With Secondary Raynaud Syndrome With Ulcers on Hands
Conditions: Raynaud's Phenomenon;   Skin Necrosis
Interventions: Drug: Tracleer;   Drug: Prostavasin
23 Completed Soluble VE-cadherin and VE-cadherin Antibody in Sclerodermic Sclerosis
Conditions: Primary Raynaud Disease;   Systemic Sclerosis
Intervention: Biological: soluble Ve cadherin
24 Recruiting PORH and Response to Cold in Raynaud's Phenomenon.
Conditions: Raynaud Disease;   Hyperemia;   Cold
Interventions: Procedure: post-occlusive hyperemia;   Procedure: cooling box;   Drug: L-NMMA and Fluconazole dermic injection
25 Completed Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon
Conditions: Raynaud's Disease;   Scleroderma;   Autoimmune Diseases
Intervention: Drug: Topical AmphiMatrix with nitroglycerin (MQX-503)
26 Completed Dose Response Study of a Topical Gel for the Treatment of Raynaud's Phenomenon
Conditions: Raynaud's Disease;   Raynaud's Disease Secondary to Scleroderma;   Raynaud's Disease Secondary to Autoimmune Disease
Intervention: Drug: MQX-503
27 Unknown  A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon
Conditions: Raynaud's Disease;   Raynaud's Disease Secondary to Scleroderma;   Raynaud's Disease Secondary to Other Autoimmune Disease
Interventions: Drug: Nitroglycerin;   Drug: Topical AmphiMatrix
28 Not yet recruiting Treatment of Digital Ulcers in Korean Patients With Systemic Sclerosis: a Prospective Cohort Study
Conditions: Raynaud Disease;   Systemic Sclerosis;   Digital Ulcer
Interventions: Drug: Calcium Channel Blockers;   Drug: Phosphodiesterase Inhibitors;   Drug: Endothelin receptor blocker;   Drug: Prostanoids;   Drug: Other vasodilator
29 Completed Dose Response to Topical Glyceryl Trinitrate in Patients With Raynaud's Phenomenon
Condition: Raynaud's Phenomenon
Interventions: Drug: placebo cream;   Drug: Glyceryl Trinitrate
30 Completed Raynaud's Treatment Study (RTS)
Conditions: Cardiovascular Diseases;   Heart Diseases;   Raynaud's Disease;   Vascular Diseases
Interventions: Drug: nifedipine;   Behavioral: biofeedback (psychology);   Procedure: electromyography
31 Active, not recruiting Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Conditions: Scleroderma;   Systemic Sclerosis;   Raynaud Phenomena;   Raynaud's Disease
Interventions: Device: Celution Device;   Other: Placebo
32 Enrolling by invitation Single-port Thoracoscopic Sympathicotomy for Treatment of Raynaud's Phenomenon, a Feasibility Study
Condition: Raynauds
Intervention: Procedure: Sympathicotomy R3
33 Recruiting Assess Efficacy of of Oral Treprostinil in Patients With Symptomatic Primary or Secondary Raynaud's Phenomenon
Condition: Raynaud's Phenomenon
Interventions: Drug: oral treprostinil;   Drug: Placebo
34 Not yet recruiting Prospective Multicenter Study on the Identification of Genetic Abnormalities Predisposing to Vasospasm From a Privileged Model: the Primary Raynaud's Phenomenon
Conditions: Primary Raynaud's Phenomenon (PR);   Genetic Mutations Causing PR;   Study of Patients and Their Relatives (With or Without Primary PR)
Intervention: Genetic: Demonstration of genetic mutations causing Raynaud's phenomenon
35 Completed "As Required" Oral Sildenafil in Raynaud's Phenomenon
Condition: Raynaud's Phenomenon
Interventions: Drug: Sildenafil 40 mg;   Drug: Sildenafil 80 mg;   Drug: Placebo
36 Completed Acupressure for the Treatment of Raynaud's Phenomenon
Condition: Primary Raynaud's Phenomeon
Interventions: Other: Acupressure;   Other: Acupressure dilatation;   Behavioral: education
37 Terminated Efficacy of ORM-12741 for Prevention of Raynaud's Phenomenon
Condition: Raynaud's Phenomenon
Interventions: Drug: ORM-12471 30mg;   Drug: ORM-12471;   Drug: placebo
38 Completed
Has Results
Efficacy Study of PDE-5 Inhibitor and Calcium Channel Inhibitor for the Treatment of Secondary Raynaud Phenomenon
Condition: Raynaud Phenomenon
Intervention: Drug: Udenafil or Amlodipine
39 Completed MQX-503 Applied to the Hand Versus Nitroglycerin Ointment Applied to the Chest: A Pharmacokinetic Comparison
Condition: Raynaud's Phenomenon
Interventions: Drug: nitroglycerin 0.9 % (MXQ-503);   Drug: Nitroglycerin ointment 2%, USP
40 Completed
Has Results
Tadalafil for the Treatment of Raynaud's
Condition: Raynaud
Intervention: Drug: Tadalafil

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-52) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.